SRR8518263
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.450
- ALLOGRAFT_REJECTION+0.440
- INTERFERON_ALPHA_RESPONSE+0.380
- INFLAMMATORY_RESPONSE+0.370
- IL6_JAK_STAT3_SIGNALING+0.340
- INTERFERON_GAMMA_RESPONSE+0.330
- MYC_TARGETS_V1+0.320
- G2M_CHECKPOINT+0.290
- IL2_STAT5_SIGNALING+0.280
- TNFA_SIGNALING_VIA_NFKB+0.270
Top 10 suppressed
- BILE_ACID_METABOLISM-0.300
- PROTEIN_SECRETION-0.300
- MYOGENESIS-0.290
- PEROXISOME-0.290
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.290
- FATTY_ACID_METABOLISM-0.260
- XENOBIOTIC_METABOLISM-0.230
- UV_RESPONSE_DN-0.220
- GLYCOLYSIS-0.190
- ADIPOGENESIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR29022833 | — | D | 0.861 |
| 2 | TCGA-S3-AA10-01A-21R-A41B-07 | — | E | 0.830 |
| 3 | TCGA-90-A4EE-01A-11R-A24Z-07 | — | cohortSQ1 | 0.827 |
| 4 | TCGA-B6-A0RT-01A-21R-A084-07 | — | D | 0.824 |
| 5 | SRR8613788 | — | D | 0.809 |
| 6 | SRR8942983 | — | — | 0.802 |
| 7 | MBCproject_0095_T3_RNA | — | E | 0.794 |
| 8 | C3N-03093 | — | cohortA1 | 0.789 |
| 9 | TCGA-A2-A0ST-01A-12R-A084-07 | — | D | 0.782 |
| 10 | MNG1010 | — | — | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.450 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.280 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |